Aberrant immunophenotype of blasts in myelodysplastic syndromes is a clinically relevant biomarker in predicting response to growth factor treatment

The use of r-HuEpo in the treatment of anaemia related to myelodysplasia (MDS)

(2010) Esther H. Rose et al.   BRITISH JOURNAL OF HAEMATOLOGY

Treatment of myelodysplastic syndrome patients with erythropoietin with or without granulocyte colony-stimulating factor: results of a prospective randomized phase 3 trial by the Eastern Cooperative Oncology Group (E1996)

(2009) P. L. Greenberg et al.   BLOOD

Standardization of flow cytometry in myelodysplastic syndromes: report from the first European LeukemiaNet working conference on flow cytometry in myelodysplastic syndromes

(2009) A. A. van de Loosdrecht et al.   HAEMATOLOGICA

Validation of a flow cytometric scoring system as a prognostic indicator for posttransplantation outcome in patients with myelodysplastic syndrome

(2008) B. L. Scott et al.   BLOOD

Erythropoietin and Granulocyte-Colony Stimulating Factor Treatment Associated With Improved Survival in Myelodysplastic Syndrome

(2008) Martin Jädersten et al.   JOURNAL OF CLINICAL ONCOLOGY

Advanced pediatric myelodysplastic syndromes: Can immunophenotypic characterization of blast cells be a diagnostic and prognostic tool?

(2008) Marinella Veltroni et al.   PEDIATRIC BLOOD & CANCER

Supportive Care and Use of Hematopoietic Growth Factors in Myelodysplastic Syndromes

(2008) Eva Hellström-Lindberg et al.   SEMINARS IN HEMATOLOGY

Predictive factors of response and survival in myelodysplastic syndrome treated with erythropoietin and G-CSF: the GFM experience

(2007) S. Park et al.   BLOOD

Flow cytometry in myelodysplastic syndromes: Report from a working conference

(2007) Michael R. Loken et al.   LEUKEMIA RESEARCH